ARK Investment Management (Cathie Wood) — RXRX Trade History

Quarter-by-quarter changes in the Recursion Pharmaceuticals Inc position · CUSIP 75629V104
Currently held · 5.3 YearsFirst seen: 2021 Q2
QuarterFiledActivitySharesΔ SharesΔ %Value% Port.
2026 Q22026-08-14Add41,337,6321,124,863+2.8%$151.7M0.98%
2026 Q12026-05-12Add40,212,7692,895,913+7.8%$123.5M0.96%
2025 Q42026-02-11Add37,316,8563,771,357+11.2%$152.6M1.01%
2025 Q32025-11-12Add33,545,499556,868+1.7%$163.7M0.97%
2025 Q22025-07-30Reduce32,988,631-1,826,871-5.2%$166.9M1.22%
2025 Q12025-05-07Add34,815,5022,469,104+7.6%$184.2M1.84%
2024 Q42025-02-04Reduce32,346,398-422,788-1.3%$218.7M1.82%
2024 Q32024-10-31Add32,769,1864,626,268+16.4%$215.9M1.98%
2024 Q22024-07-26Add28,142,9183,555,357+14.5%$211.1M1.87%
2024 Q12024-04-18Add24,587,5613,933,274+19.0%$245.1M1.70%
2023 Q42024-01-17Add20,654,28713,777,689+200.4%$203.7M1.21%
2023 Q32023-10-18Add6,876,5982,138,081+45.1%$52.6M0.40%
2023 Q22023-07-10Add4,738,5171,161,655+32.5%$35.4M0.23%
2023 Q12023-04-17Add3,576,862477,372+15.4%$23.9M0.16%
2022 Q42023-01-24Reduce3,099,490-260,321-7.7%$23.9M0.21%
2022 Q32022-10-17Add3,359,811627,724+23.0%$35.7M0.25%
2022 Q22022-07-11Reduce2,732,087-95,076-3.4%$16.7M0.10%
2022 Q12022-04-19Add2,827,163595,150+26.7%$20.2M0.08%
2021 Q42022-01-28Reduce2,232,013-361,823-13.9%$38.2M0.12%
2021 Q32021-11-12Add2,593,836215,161+9.0%$59.7M0.14%
2021 Q22021-08-05New2,378,6752,378,675$86.8M0.16%
2021 Q12021-05-13
2020 Q42021-02-12
2020 Q32020-10-30
2020 Q22020-08-11
2020 Q12020-05-14
2019 Q42020-01-31
2019 Q32019-11-12
2019 Q22019-07-30
2019 Q12019-05-13
2018 Q42019-02-11
2018 Q32018-11-07
2018 Q22018-08-07
2018 Q12018-05-14
2017 Q42018-02-12
2017 Q32017-11-09
2017 Q22017-08-11
2017 Q12017-05-15
2016 Q42017-02-13

Share counts are split-adjusted. Time held counts consecutive quarters ending with the latest filing; more than ten years shows as ">10 Years".

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.